Research location
Takatsuki
Osaka, Japan
Advertisement
Research activity in Takatsuki
Osaka, JapanCureCurrent currently publishes aggregate city-level research activity for this location: 73 trials and 77 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Takatsuki
73 linked trials · page 1 of 2A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08 · 1 site observation
RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaNCT06882785 · 2025-06-10 · 2 site observations
RECRUITING
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation
RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25 · 1 site observation
RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787 · 2024-09-26 · 1 site observation
RECRUITING
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)NCT06345729 · 2024-05-24 · 1 site observation
RECRUITING
A Study of KK2269 in Adult Participants With Solid TumorsNCT06266299 · 2024-01-18 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788 · 2023-12-15 · 1 site observation
RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)NCT05980949 · 2023-07-11 · 1 site observation
RECRUITING
Special Drug Use Surveillance of Entresto Tablets (Hypertension)NCT05976230 · 2023-09-04 · 1 site observation
COMPLETED
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan ExtensionNCT06212752 · 2023-06-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)NCT05722015 · 2023-02-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection TherapyNCT05463744 · 2022-08-12 · 1 site observation
COMPLETED
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)NCT05298423 · 2022-05-03 · 1 site observation
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal InsulinNCT05275400 · 2022-03-08 · 1 site observation
COMPLETED
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerNCT06525246 · 2021-08-06 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)NCT04956692 · 2021-08-05 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 1 site observation
TERMINATED
A Study of Tirzepatide (LY3298176) in Participants With Obesity DiseaseNCT04844918 · 2021-05-10 · 1 site observation
COMPLETED
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)NCT04738487 · 2021-04-07 · 1 site observation
TERMINATED
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension PhaseNCT04825860 · 2021-03-29 · 1 site observation
TERMINATED
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerNCT04702880 · 2021-03-17 · 1 site observation
COMPLETED
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)NCT04624204 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsNCT04593927 · 2020-10-28 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%NCT04435626 · 2020-09-14 · 1 site observation
COMPLETED
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)NCT04380636 · 2020-07-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511 · 2020-06-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ TabletsNCT04340115 · 2020-04-24 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without MetforminNCT04039503 · 2019-08-30 · 1 site observation
COMPLETED
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)NCT03924869 · 2019-06-25 · 1 site observation
TERMINATED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneNCT03954834 · 2019-06-03 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 DiabetesNCT03861052 · 2019-05-07 · 1 site observation
COMPLETED
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesNCT03861039 · 2019-03-30 · 1 site observation
COMPLETED
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also StudiedNCT03639675 · 2018-10-03 · 1 site observation
COMPLETED
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEFNCT03547583 · 2018-06-15 · 2 site observations
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)NCT03221426 · 2017-10-09 · 1 site observation
COMPLETED
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)NCT03189719 · 2017-07-25 · 1 site observation
COMPLETED
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection FractionNCT03098979 · 2017-05-10 · 2 site observations
COMPLETED
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection FractionNCT02992288 · 2017-02-22 · 1 site observation
COMPLETED
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaNCT02554786 · 2015-12-29 · 1 site observation
COMPLETED
Asthma Control, Quality of Life and Emotional Feelings in a Real Life SettingNCT02640742 · 2015-12-18 · 2 site observations
COMPLETED
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast CancerNCT02598310 · 2015-11-01 · 1 site observation
TERMINATED
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease ParticipantsNCT02337751 · 2015-07-10 · 1 site observation
COMPLETED
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection FractionNCT02468232 · 2015-06-15 · 1 site observation
COMPLETED
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma PatientsNCT02396316 · 2015-04-02 · 1 site observation
COMPLETED
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsNCT02337725 · 2015-02-07 · 1 site observation
COMPLETED
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsNCT02337738 · 2015-01-27 · 1 site observation
COMPLETED
Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM PatientsNCT02002221 · 2013-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.